Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive results for Welichem’s lead anticancer agent
The results from work done at the Centre of Translational Research in Cancer of the Jewish General Hospital in Montreal showed a potent delay of tumor growth following
The results from work done at the Centre of Translational Research in Cancer of the Jewish General Hospital in Montreal showed a potent delay of tumor growth following
Avastin, which is already approved by the FDA as a first-line treatment for metastatic colorectal cancer, is designed to interfere with the blood supply to tumors, a process
Neurologix’s 12-patient, dose-escalating phase I trial is the world’s first study to use a viral vector (the non-pathogenic adeno-associated virus, or AAV) for the treatment of an adult
This technique is so sensitive that even when these cancer markers constitute only one hundred-billionth of the protein present in a drop of blood it is still detectable.
The protein, known as raf kinase inhibitor protein (RKIP) controls activity of kinases, a type of enzyme that acts as a key component in the biochemical signaling pathways
Neuralgic amyotrophy (HNA), a rare hereditary disease, is characterized by repeated attacks of pain in a shoulder, arm, and/or hand, followed by total or partial paralysis of the
The new treatment was co-developed in the laboratories at the Medical College in cooperation with Taisho scientists. The Research Foundation awarded Taisho exclusive world-wide rights to further develop
The commencement of the trial had been expected at the end of 2005, but is now expected to move into 2006. An accelerated stability study of a vaccine
These neurodegenerative diseases share an abnormal deposit of proteins inside nerve cells. This deposition of protein results from a kind of genetic stutter within the cell’s nucleus asking
IFN-alpha-XL utilizes nanoparticle technology to provide a long-acting formulation of interferon alpha that may have enhanced efficacy and reduced toxicity compared with unmodified or PEG-modified interferon formulations. “Interferon